Westlake Village-based Angitia Biopharmaceuticals, a clinical-stage biotechnology company developing novel therapies aimed at improving musculoskeletal health, announced that it has closed $130 million in a Series D financing round. Announced Feb. 5, Angitia’s Series D round was led by Frazier Life Sciences and Venrock Healthcare Capital Partners, with participation from new investors: Ascenta Capital, certain…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
